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Pulmonary transplantation is currently limited by the number of suitable 
cadaver donor lungs. For this reason, pulmonary xenotransplantation is
currently being investigated. Objective: Our goal was to assess the role of 
complement in pulmonary xenograft dysfunction. Methods: The pulmonary 
function of swine expressing human decay accelerating factor and human 
CD59 (n = 6) was compared with that of the lungs from nontransgenic 
(control) swine (n = 6) during perfusion with human plasma. Results: After 
2 hours of perfusion, the pulmonary vascular resistance was 1624 -- 408 
dynes.sec, cm -5 in control lungs and 908 -+ 68 dynes.sec, cm -s in 
transgenic lungs (p < 0.05). Control lungs had a venous oxygen tension of 
271 -- 23 mm Hg with a ratio of venous oxygen tension to inspired oxygen 
fraction of 452 -+ 38 at 2 hours of perfusion; transgenic lungs had a venous 
oxygen tension of 398 __ 11 mm Hg and a ratio of venous oxygen tension to 
inspired oxygen fraction of 663 -- 18 (p < 0.05). Control lungs showed a 
decrease of 79.8% -- 3.7% in static pulmonary compliance by 2 hours, 
versus a 12.0% -- 8.1% decrease by the transgenic lungs (p < 0.05). The 
control lungs also developed 561.7 __ 196.2 ml of airway edema over 2 
hours, in contrast to 6.5 -+ 1.7 ml in transgenic lungs (p < 0.05). Conclusion: 
Lungs from swine expressing human decay accelerating factor and human 
CD59 functioned better than nontransgenic swine lungs when perfused with 
human plasma. These results suggest that complement activation is 
involved in producing acute pulmonary xenograft dysfunction and demon- 
strate that lungs from swine expressing human decay accelerating factor 
and human CD59 are protected against pulmonary injury when perfused 
with human plasma. (J Thorac Cardiovasc Surg 1997;113:390-8) 
S ince the first clinical lung transplantation by James Hardy in 1963,1 improvements in surgical 
technique and advances in immunosuppression have 
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made this procedure the most rapidly growing area 
in solid organ transplantation. 2 As is the case for 
other organs, donor availability continues to be a 
limiting factor in performing these procedures. 3 
Because only 10% to 20% of cadaveric donors have 
lungs suitable for pulmonary transplantation, 4 and 
because no acceptable long-term mechanical re- 
placement is currently available for the lung, the use 
of animals for lung donors is being considered. 
Swine were chosen as a potential ung donor source 
because of their domestication, anatomic similari- 
ties to human beings, short gestational period, and 
rapid growth. 
Complement-mediated hyperacute rejection pre- 
sents a major barrier to the successful transplanta- 
tion of vascularized xenografts. 5 This process is 
associated with endothelial damage, coagulation, 
cellular and platelet adherence, and accelerated 
capillary leak. 6 Although hyperacute rejection has 
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Fig. 1. Diagram of isolated working lung apparatus. Plasma enters the pulmonary artery under gravity 
from the upper eservoir at a height of 45 cm above the pulmonary artery. Plasma is allowed to drain into 
the lower reservoir, where carbon dioxide is added by a diffuser. The roller pump recirculates the plasma 
from the lung chamber to the upper eservoir, where it is warmed to 37 ° C by a heat exchanger. The lung 
is ventilated with 60% oxygen at a rate of 12 breaths/min. PA, Pulmonary artery; PV, pulmonary vein; RR, 
respiratory ate; PIAP, peak inspiratory airway pressure. 
been studied extensively in heart and kidney xeno- 
grafts, the role of complement in pulmonary xeno- 
graft rejection is a subject of controversy. Investiga- 
tion of pulmonary xenograft rejection has been 
hindered by the lack of a good model. Very limited 
pulmonary flow during prior attempts to perfuse 
swine lungs with human blood products has pre- 
vented the examination of the mechanisms of rejec- 
tion in these models] Furthermore, no good immu- 
nohistologic markers have been found in association 
with pulmonary xenograft injury. In contrast o 
other vascularized xenografts, wine-to-primate pul- 
monary xenografts do not show the deposition of 
activated complement products on their endothe- 
lium despite functional failure and the appearance 
of rejection on gross examination. 8 
Because the complement-regulatory proteins of 
swine are incompatible with the human complement 
system, swine xenografts are excessively susceptible 
to complement-mediated injury. One approach to 
overcome this problem is to express human comple- 
ment-regulatory proteins in the donor animal. 9'10 
Transgenic swine have been created that consti- 
tutively express the human complement-regula- 
tory proteins, decay accelerating factor (hDAF) 
and CD59 (hCD59). DAF accelerates the decay of 
C3 convertase, an enzyme responsible for the 
amPlification of both the classical and alternative 
complement pathways. CD59 acts by preventing 
assembly of the membrane attack complex. The 
expression of hDAF and hCD59 in these animals 
has been shown to be effective in preventing 
hyperacute r jection, as demonstrated bythe pro- 
longation of cardiac xenograft survival in the 
swine-to-primate model. 1° 
To investigate he ability of transgenic swine lungs 
to resist he acute pulmonary injury seen when swine 
lungs are exposed to human plasma, we studied the 
pulmonary hemodynamics, aerodynamics, gas ex- 
change, and development of edema of nontransgenic 
and hDAF/hCD59 transgenic swine lungs perfused 
with human plasma in an isolated working lung model. 
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Fig. 2. PVR of isolated swine lungs perfused with human plasma. '*7) < 0.05 (analysis of variance), 
transgenic versus control over time. 
Mater ia ls  and  methods  
Swine. Adult swine (60 to 75 kg) transgenic for hDAF 
and hCD59 were supplied by Nextran, Princeton, New 
Jersey. The ~-actin-CD59 transgene contains a chick 
/3-actin promoter, controlling expression of complemen- 
tary DNA hCD59. The H2Kb-DAF transgene contains a 
mouse H2K b promoter, which regulates expression of 
complementary DNA hDAF. These swine have demon- 
strated the expression of hDAF and hCD59 messenger 
ribonucleic acid in the lung and other tissues. ~1 Functional 
expression of human complement-regulatory proteins was 
confirmed by a three- to fivefold resistance of peripheral 
blood lymphocytes to human complement-mediated ly- 
sis. 11 All nontransgenic (60 to 75 kg) adult swine were 
obtained from Walnut Hill Farms, Hillsborough , North 
Carolina. 
Lung harvesting. All animals received humane care in 
compliance with the "Guide for the Care and Use of 
Laboratory Animals" published by the National Institutes 
of Health (NIH publication No. 86-23, revised 1985). 
Animals were anesthetized with intramuscular dministra- 
tion of ketamine hydrochloride (20 mg/kg) and intrave- 
nous fentanyl (5 ~g/kg). Animals were intubated and 
ventilated with 100% oxygen at a rate of 10 breaths/min 
with a tidal volume of 12 ml/kg. Arterial pressure and 
blood gases were monitored through cannulation of the 
right femoral artery. A median sternotomy and thymec- 
tomy were performed and the pericardium was opened. 
The azygos and hemiazygos veins were ligated and the 
inferior and superior venae cavae were loosely encircled 
with umbilical tape. Prostaglandin E~ (50 txg/kg) was 
injected directly into the pulmonary artery and heparin 
was administered intravenously (500 U/kg) 10 minutes 
before harvest. The venae cavae were ligated and the left 
and right atria were incised to allow for venting during the 
preservation process. Euro-Collins solution (25 ml/kg) 
was administered into the pulmonary artery from a height 
of  30 cm. The inferior pulmonary ligaments were sharply 
divided and the trachea was divided with a stapling device. 
The heart and lungs were then removed en bloc and 
immersed in cold (4 ° C) saline solution. Lungs were 
separated and cannulas were placed into the main bron- 
chus and pulmonary artery and secured with suture liga- 
tures. The total ischemic time in both groups was consis- 
tently less than 35 minutes. 
Isolated lung apparatus. The isolated lung apparatus 
was constructed as shown in Fig. 1. Lungs were ventilated 
with an adult volume-controlled ventilator (Bennett Res- 
piration Products, Inc., Santa Monica, Calif.) with 60% 
oxygen at a rate of 10 breaths/min, adjusting the tidal 
volume to maintain the peak airway pressure at 35 cm 
H20. Perfusion was achieved by delivering the plasma to 
the pulmonary artery from a reservoir at a height of 45 cm 
above the pulmonary artery. The perfusate was collected 
into a lower reservoir and recirculated through a 20 ~m 
filter (Pall Biomedical, Inc., Fajardo, Puerto Rico) to the 
upper reservoir by a roller pump (Sarns Inc., Ann Arbor, 
Mich.). The temperature of the perfusate was maintained 
at 37°C by a heat exchanger (Medtronic Cardiopulmo- 
nary, Anaheim, Calif.) inside the upper reservoir. 
Preparation of human plasma used for perfusion. The 
perfusate for each lung consisted of 5 pooled units (175 to 
225 ml) of type O rhesus + fresh human plasma (Amer- 
ican Red Cross, Durham, N.C.). The plasma was thawed 
to 30°C in a water bath and heparinized with heparin 
sodium (16 U/m1) before pooling. The pooled plasma was 
combined with a 40% volume of lactated Ringer's s01u- 
tion. Sodium bicarbonate, magnesium sulfate, and cal- 
cium chloride were added to the solution for a final 
composition of pH 7.4, bicarbonate 25 mmol/L, potassium 
4 mmol/L, calcium ++ 1.2 mmol/L, magnesium 1.0 
mmol/L, and sodium 140 mmol/L. The plasma solution 
was briefly circulated before perfusion, being warmed to 
37 ° C, and carbon dioxide was directly diffused into the 
upper reservoir maintaining the carbon dioxide tension 
between 35 and 45 mm Hg. 
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Fig. 3. Ratio of oxygen tension (ram Hg) in pulmonary venous ample (Po2) divided by the fraction of 
inspired oxygen (Fio2). *p < 0.05 (t test), transgenic versus control at 120 minutes of perfusion with human 
plasma. 
Data acquisition. Pulmonary artery flow was measured 
with an ultrasonic in-line flowmetcr (Transonics Systems, 
Inc., Ithaca, N.Y.) and pulmonary artery pressure was 
determined with a Millar Mikro-Tip micromanometer 
(Millar Instruments, Inc., Houston, Tex.) positioned in 
the proximal pulmonary artery. Blood gases were mea- 
sured with a Gem-Star blood gas analyzer (Mallinckrodt 
Sensor Systems, Inc., Ann Arbor, Mich.) from pulmonary 
venous samples. End-expiratory volume and pressure 
were measured with an adult volume-controlled ventilator 
(Bennett Respiration Products, Inc., Santa Monica, Cal- 
if.). Edema was measured by the volume of fluid accumu- 
lation in the airway during the procedure. 
Immunohistochemistry. Lung biopsy specimens were 
taken before perfusion. Inflated lung specimens were 
snap-frozen in precooled isopentane and stored at 
-80 ° C. Frozen tissue sections (4 /~m thick) were pre- 
pared in a Leica cryostat (Leica, Heidelberg, Germany). 
The sections were air-dried, fixed with acetone, and 
washed with phosphate-buffered saline solution. Each 
section was then incubated with a fluorescein isothiocya- 
nate-conjugated primary reagent (rabbit antibody to 
hDAF, rabbit antibody to hCD59, or the GS-I-B4 lectin 
[Vector Laboratories, Burlingame, Calif.], which has spe- 
cific binding to c~-1,3 galactose). Tissue sections were 
washed with phosphate-buffered saline solution after in- 
cubations and mounted with p-phenylenediamine/glycerol 
solution. Sections were evaluated with a Leitz DMRB 
epifluorescence microscope (Leica) and photographed. 
Statistical analysis. Data (given as the mean _+ stan- 
dard error of the mean) were analyzed by two-way analysis 
of variance with SigmaStat statistical analysis software 
(Jandel Scientific, San Rafael, Calif.) and considered 
significant at the p < 0.05 level. 
Results 
Pulmonary vascular resistance. Control lungs 
(n = 6) displayed a higher pulmonary vascular 
resistance (PVR) over time than transgenic lungs 
(Fig. 2) (p < 0.05). At the end of 2 hours, control 
lungs had a pulmonary flow of 1102 _+ 117 ml/min 
and a PVR of 1624 +_ 408 dynes-sec .cm -5, 
whereas transgenic lungs (n = 6) had a pulmonary 
flow of 1388 _+ 46 ml/min and a PVR of 908 _ 68 
dynes, sec. cm -s. 
Gas exchange. The gas exchange of the lungs was 
assessed by calculating the ratio of pulmonary ve- 
nous oxygen partial pressures (Pvo2, mm Hg) to 
inspired oxygen (Fio2). Transgenic lungs displayed 
better oxygenation than control ungs after 2 hours 
of perfusion. After 1 hour of perfusion, control 
lungs had a Pvo2 of 288 + 24 mm Hg with a 
Pvo2/Fio2 of 480 + 40; transgenic lungs had a Pvo 2 
of 352 + 10 mm Hg and a Pvoz/Fio2 of 587 _+ 17 
(p = 0.05). After 2 hours of perfusion, control ungs 
had a Pvoe of 271 _+ 23 mm Hg with a PvoJFio2 of 
452 _+ 38 and transgenic lungs, a Pvo 2 of 398 _+ 11 
mm Hg and a Pvoz/Fio 2 of 663 +_ 18 (p < 0.05) (Fig. 
3). 
Compliance. Transgenic lungs had significantly 
greater etained compliance over time than control 
lungs. Control swine lungs began to lose compliance 
within the first minute of perfusion with human 
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Fig. 4. Static pulmonary compliance of isolated swine lungs perfused with human plasma (shown as 
percentages of initial values). *p < 0.05 (t test), transgenic versus control at individual time points. 
plasma (Fig. 4). The decline in compliance appeared 
to correlate with the development of pulmonary 
edema. After 120 minutes of perfusion, the control 
lungs had a 79.8% + 3.7% reduction in static 
pulmonary compliance. In contrast, there was little 
change in the compliance of hDAF/hCD59 lungs 
during the 2 hours of perfusion, with only a 12.0% _+ 
8.1% reduction in static pulmonary compliance by 
the end of 2 hours of perfusion (p < 0.05). 
Pulmonary edema. Edema consistently devel- 
oped within minutes of perfusion in control ungs. 
After 2 hours of perfusion of control ungs, edema 
formation progressed to the extent (561.7 _+ 196.2 
ml) that the reservoir volume was significantly de- 
pleted, thus limiting the study period to 2 hours. 
Transgenic lungs displayed an impressive protection 
from the development of edema during the 2-hour 
study period, with 6.5 _+ 1.7 ml of airway fluid 
accumulation (p < 0.05) (Fig. 5). 
Immunohistoehemistry. Biopsy specimens of 
lung tissue were taken before perfusion and stained 
for the presence of hDAF and hCD59. Both hDAF 
and hCD59 were found to be present on the pulmo- 
nary endothelium in transgenic swine lungs and 
absent in nontransgenic lungs (Fig. 6). Immunoflu- 
orescent staining for GS-I-B4 lectin was not differ- 
ent between transgenic and nontransgenic lungs. 
Discussion 
Investigation of pulmonary xenoperfusion began 
with the early development of cardiopulmonary 
bypass, during which canine lungs were used to 
oxygenate human blood. 12 In these studies, the rapid 
development of edema and high PVR limited pul- 
monary function to 15 to 20 minutes. 12' 13 In 1968, 
Bryant, Eiseman, and Avery 13 reported similar re- 
sults in swine lungs perfused with human blood, 
achieving less than 10% of adult human pulmonary 
blood flow. Rapid development of edema, loss of 
blood flow, and subsequent deterioration of gas 
exchange has been noted in each of these reports 
and in other studies of pulmonary xenoperfu- 
sion.7, 12-14 Although these phenomena have been 
consistently reported, the mechanisms causing these 
processes have not been elucidated. 
The development of airway edema nd decreased 
gas exchange in control swine lungs in this study is 
consistent with prior reports of pulmonary heterol- 
ogous perfusion. The protection of swine lungs 
expressing human complement-regulatory proteins 
from human plasma implies that complement plays 
an important role in pulmonary xenograft rejection. 
The transgenic swine used in this study have dem- 
onstrated expression of hDAF and hCD59 in the 
lung, as well as in other tissues. *~ The hDAF and 
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Fig. 5. Total amount of edema formation after 120 minutes of perfusion with human plasma. *p < 0.05 
(t test), transgenic versus control at 120 minutes of perfusion with human plasma. 
hCD59 proteins are functional, as measured by 
protection of peripheral swine lymphocytes from 
human complement lysis. 11 And hearts from these 
same transgenic swine have been shown to over- 
come complement-mediated hyperacute rejection 
when transplanted into baboons) ° 
The significance of complement-regulatory p o- 
teins in preventing hyperacute rejection rests in the 
ability to inhibit species-specific complement activa- 
tion. These membrane-bound proteins are relatively 
restrictive, such that an organ transplanted into a 
recipient of a phylogenetically disparate species 
does not have the ability to regulate the activation of 
complement in the recipient, is Inasmuch as recipi- 
ent complement is highly activated by a xenograft 
and the xenograft does not have the ability to 
regulate this activation, complement activation con- 
tinues uninhibited. This results in the generation 
and deposition of terminal complement complexes 
and leads to hyperacute rejection. A promising new 
development in the field of xenotransplantation has 
been the creation of animals expressing human 
complement-regulatory proteins. 
The isolated lung model used in this study facili- 
tates accurate measurements of hemodynamic and 
aerodynamic parameters and has several features 
that distinguish it from an in vivo pulmonary xeno- 
graft. One element, in particular, is the use of 
plasma as opposed to whole blood. Plasma was 
chosen as a perfusate to examine the humoral 
immune response free from the effects of platelets 
and celbmediated processes. The complex interac- 
tions between humoral and cellular elements in 
whole blood, which may contribute to the loss of 
pulmonary xenograft function, do not take place in 
this model. 16' 17 For example, the increase in PVR in 
this study, while significant, is considerably ess than 
previously reported when whole blood was used as a 
perfusate.7, 23, 14 Platelets in the perfusate may con- 
tribute to the development of increased PVR 
through the release of thromboxane A 2 from acti- 
vated platelets. In addition, neutrophils activated by 
complement are known to contribute to pulmonary 
injury through several different mechanisms, includ- 
ing the generation of oxygen-derived free radicals) 8
The absence of neutrophils in this model removes 
this potentially relevant process. Furthermore, ex- 
tracorporeal circulation has been shown to cause 
pulmonary injury in association with homologous 
complement activation through the alternative path- 
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Fig. 6. Immunofluorescent micrographs of nontransgenic (A) and transgenic swine lung tissue (B) and 
human lung tissue (C) stained with fluorescent rabbit antibody to hDAF (left) and hCD59 (right) before 
perfusion with human plasma. 
way such as occurs with cardiopulmonary b pass. 19 
Although the length of cardiopulmonary b pass is 
associated with increasing complement activation 
and pulmonary injury, 2° the degree of pulmonary 
injury and loss of function associated with extracor- 
poreal circulation is relatively minor compared with 
the profound lung injury manifest by the immediate 
development of massive pulmonary edema and pul- 
monary vasoconstriction bserved in heterologously 
perfused lungs. 7' 22-14 
Although the mechanisms of injury in heterolo- 
gously perfused lungs have not been defined, they 
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differ from those described in other vascularized 
xenografts. 6 Hyperacute rejection of heart and kid- 
ney xenografts i caused by the binding of xenore- 
active antibodies to antigens expressed on the endo- 
thelial surface of the xenograft. The most important 
antigen is believed to be ~-1,3 galactose. Comple- 
ment activation through the classical pathway has 
been shown to be an integral component in the 
process of hyperacute r jection of heart and kidney 
xenografts. 5'6 After hyperacute rejection of the 
heart or kidney, complement deposition is present 
in abundance on the endothelial surface. 6 Although 
complement activation occurred uring perfusion of 
both transgenic and nontransgenic lungs in the 
present study, as measured by a three- to fivefold 
increase in the levels of C3a-desArg, endothelial 
complement deposition is minimal (data not 
shown), as has been previously reported by Kaplon 
and colleagues 8 in orthotopic swine-to-primate pul- 
monary xenografts. 
A potential limitation of this study is the lack of 
demonstrable difference in complement activation 
between the transgenic and nontransgenic groups. 
However, the swine used for the study were not 
inbred, they were of similar age and weight, and they 
expressed the o~-1,3 galactose antigen similarly. The 
only observable difference between transgenic and 
nontransgenic swine in this study was the presence 
of the hDAF and hCD59 in the transgenic swine, 
which were associated with profound ifferences in
pulmonary function after heterologous perfusion. 
In modeIs of complement inhibition using the 
soluble complement receptor, sCR1, or depletion of 
complement with cobra venom factor, hyperacute 
cardiac rejection is prevented and prolongation of 
xenograft survival has been achieved for up to 25 
days.2t, 22 In contrast, in a study by Pierson and 
associates, 7 neither cobra venom factor nor heat 
treatment was effective in preventing pulmonary 
rejection when swine lungs were perfused with hu- 
man blood. However, the protection of swine lungs 
expressing human complement-regulatory proteins 
from damage by human plasma in the current study 
implies that complement is involved in this process. 
This discrepancy may be related to the particular 
methods of complement depletion. Because cobra 
venom factor and heat treatment of whole blood 
may increase the release of vasoactive substances 
and stimulate coagulation, it may be that the 
method used to deplete complement actually con- 
tributed to the profound pulmonary hypertension 
observed in that study. 
In conclusion, lungs from swine expressing the 
human complement-regulatory proteins, hDAF and 
hCD59, were consistently protected against in- 
creased PVR, decreased ability to transport oxygen, 
loss of compliance, and development of edema 
when perfused with human plasma. This study im- 
plies that complement is involved in pulmonary 
xenograft injury and suggests that transgenic swine 
may lead to a useful source for expanding the 
pulmonary donor pool. 
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Discussion 
Dr. Richard N. Pierson II I (Nashville, Tenn.). This 
study demonstrates conclusively that complement is in 
fact involved in the hyperacute rejection process of pig 
lungs by human blood and is an important contribution to 
our understanding of that process. My questions are three. 
Have you looked for evidence of endothelial cell activa- 
tion in the context of these plasma-perfused pig lungs, 
which would be important hen in other processes that 
might occur later in the hyperacute rejection process? 
Second, do you have any information on perfusion of 
these lungs with whole blood as opposed to cell-free 
plasma? Third, I noticed that you had a Pall filter in your 
perfusion circuit. Why did you think that was an important 
thing to have? 
Dr. Daggett. Thank you, Dr. Pierson. We did not 
evaluate ndothelial cell activation in this study but are 
currently evaluating such using electron microscopy. In 
answer to your second question, the results obtained, 
transplanting these transgenic swine lungs orthotopically 
into baboons, demonstrated that they were protected 
from acute pulmonary dysfunction. To answer your third 
question about the Pall filter, we thought hat the chance 
of embolizing those lungs with fibrin or other cellular 
debris was an important factor in determining the PVR 
and could contribute to the decline in pulmonary function. 
Therefore, to prevent his from occurring, we chose to 
have a filter in the circuit. 
Dr. Dao Mirth Nguyen (Houston, Tex.). Have you have 
expanded your experiment beyond 120 minutes? If so, 
what happened to the transgenic lung? 
Dr. Daggett. In this model and in other ex vivo models, 
there tends to be a decline in function of an organ over 
time. Even when swine lungs are perfused with autologous 
plasma, after approximately 21/2 hours of perfusion the 
model begins to deteriorate. The limiting factor in this 
study, however, was pulmonary edema formation in the 
control lungs. After 120 minutes, the pulmonary edema 
caused sufficient loss in the reservoir volume and limited 
this study to 120 minutes. 
Dr. Larry R. Kaiser (Philadelphia, Pa.). Have you 
evaluated these lungs histologically, and can you describe 
your findings? 
Dr. Daggett. We have looked at the histology and 
immunopathology in these lungs. An interesting feature of 
pulmonary xenografts, as opposed to the heart and the 
kidneys, is that they do not display either the xenoreactive 
antibodies or products of complement activation on their 
endothelial surface. One possible explanation for this is 
that the endothelial surface of the lungs is approximately 
97 times greater than that of the heart. An immunofluo- 
rescent stain would be expected to be distributed over 97 
times the area, which may not show up as much. The other 
histologic features of pulmonary xenograft rejection in our 
models seemed to include several things: the massive infil- 
tration of leukocytes, the formation of platelet and fibrin 
plugs, and the disruption of alveoli in the lungs. These 
processes were all found to be considerably ess when we 
used transgenic hCD59 and hDAF lungs in this model. 
Dr. Keith Naunheim (St. Louis, Mo 0. Dr. Daggett, have 
you considered oing bronchoscopy with bronchoalveolar 
lavage to look at the number of macrophages you can 
harvest and the cytokine profile? 
Dr. Daggett. We have not investigated that. 
